Drug treatment of gliomas

Hoffmann, Johannes and Hau, Peter and Pukrop, Tobias and Karthaus, Meinolf (2019) Drug treatment of gliomas. ONKOLOGE, 25 (1). pp. 53-59. ISSN 0947-8965, 1433-0415

Full text not available from this repository. (Request a copy)

Abstract

BackgroundGliomas have specific features in terms of diagnosis, classification and treatment compared to other solid tumors that need to be considered. In particular, the vulnerability of the affected organ the brain requires careful planning of surgical, radiotherapeutic and systemic treatment as well as careful support and treatment counseling of affected patients.MethodA selective literature search was carried out.ResultsWithout an integrated diagnosis of histomorphological and molecular criteria, astratified treatment is not possible. Due to the mostly diffuse infiltrating character of the disease, systemic therapy is of crucial importance both in the initial treatment as well as in recurrence and progression. Due to a rapid increase in the knowledge of underlying molecular and genetic changes leading to tumorigenesis, a further diversification into different entities can be expected in the future, which could expand the treatment options.ConclusionDogmas, such as an immune privilege of the central nervous system (CNS) and alack of CNS accessibility of drugs due to the blood-brain barrier, lose importance in the context of modern treatment options, such as small molecules, antibodies or immuno-oncological therapeutics. Further clinical and preclinical research is urgently needed to improve the still poor prognosis for many glioma patients.

Item Type: Article
Uncontrolled Keywords: PHASE-III TRIAL; GLIOBLASTOMA; TEMOZOLOMIDE; OLIGODENDROGLIOMA; RADIOTHERAPY; BEVACIZUMAB; PSEUDOPROGRESSION; CHEMOTHERAPY; ASTROCYTOMA; STRATEGIES; Brain tumors; Integrated diagnosis; Temozolomide; Targeted therapy; Small molecules
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 Apr 2020 07:27
Last Modified: 22 Apr 2020 07:27
URI: https://pred.uni-regensburg.de/id/eprint/27907

Actions (login required)

View Item View Item